Naslov
The role of Body Mass Index in response to therapy in diffuse large B cell lymphoma patients

Autori
Duletić-Načinović, Antica ; Marijić, Blažen ; Grubešić, Aron ; Sokolić, Žana ; Dobrila - Dintinjana, Renata

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
6th International Congress of Croatian Association for Protection of Non Ionizing Radiation VIIth Meeting of Experts for Influence in Optical Radiations & Electromagnetis Fields on Human IInd Meeting of Experts for the Quality of Life Problems in the Senior Population

Mjesto i datum
Opatija, Hrvatska, 26.04.2014. - 27.04.2014

Vrsta sudjelovanja
Poster

Vrsta recenzije
Nije recenziran

Ključne riječi
Body Mass Index; lymphomas; prognostic factors; responese to therapy
(Body Mass Index; lymphomas; prognostic factors; response to therapy)

Sažetak
Background: Obesity is a well-known risk factor for the development of several types of cancer including lymphomas, but its influence on the course of this disease is fairly unknown. Despite detailed evaluation of disease-associated prognostic factors, little is known about the impact of overweight in therapy outcomes in patients with diffuse large B cell lymphoma (DLBCL). The aim of this study was to analyse the association between Body Mass Index (BMI) and response to therapy in patients who were newly diagnosed as DLBCL. Also, we wanted to investigate a possible clinical usefulness of Body Mass Index as prognostic factor, for treatment response in patients with this disease. Patients and methods: This retrospective single-center analysis included 94 DLBCL patients who were treated with rituximab and standard-dosed antracycline-based chemotherapy as a first-line therapy. BMI was categorized based on current World Health Organization definitions. The primary endpoint of this research was patients response to applied therapy. Results: Among patients with DLBCL the median age was 66 years. 38% were overweight. No significant association was reported between BMI and response to therapy (p=0, 543), International Prognostic Index (p= 0, 712), Eastern Oncology Cooperative Group performance status (p= 0, 835), Ann Arbor stage (p=0, 996) and B symptoms of disease (p=0, 356). Conclussion: BMI was not significantly associated with clinical outcomes among patients with DLBCL. These findings contradict some previous reports of similar investigations. Further work is required to understand the observed discrepancies.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti

POVEZANOST RADA